Prognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients

Sarah Parisi,1 Carlo Finelli2 1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy; 2IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Parisi S, Finelli C
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	iron overload myelodysplastic syndrome iron chelation therapy hepcidin Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/13fa4193da1b4fd292ba8f964c3b6833
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:13fa4193da1b4fd292ba8f964c3b6833
record_format	dspace
spelling	oai:doaj.org-article:13fa4193da1b4fd292ba8f964c3b68332021-12-05T18:27:45ZPrognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients1179-2736https://doaj.org/article/13fa4193da1b4fd292ba8f964c3b68332021-12-01T00:00:00Zhttps://www.dovepress.com/prognostic-factors-and-clinical-considerations-for-iron-chelation-ther-peer-reviewed-fulltext-article-JBMhttps://doaj.org/toc/1179-2736Sarah Parisi,1 Carlo Finelli2 1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy; 2IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, ItalyCorrespondence: Sarah Parisi Email sarah.parisi2@unibo.itAbstract: Iron chelation therapy (ICT) is an important tool in the treatment of transfusion-dependent lower-risk myelodysplastic syndrome (MDS) patients. ICT is effective in decreasing iron overload and consequently in limiting its detrimental effects on several organs, such as the heart, liver, and endocrine glands. Besides this effect, ICT also proved to be effective in improving peripheral cytopenia in a significant number of MDS patients, thus further increasing the clinical interest of this therapeutic tool. In the first part of the review, we will analyze the toxic effect of iron overload and its mechanism. Subsequently, we will revise the clinical role of ICT in various subsets of MDS patients (low, intermediate, and high risk MDS, patients who are candidates for allogeneic stem cell transplantation).Keywords: iron overload, myelodysplastic syndrome, iron chelation therapy, hepcidinParisi SFinelli CDove Medical Pressarticleiron overloadmyelodysplastic syndromeiron chelation therapyhepcidinDiseases of the blood and blood-forming organsRC633-647.5ENJournal of Blood Medicine, Vol Volume 12, Pp 1019-1030 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	iron overload myelodysplastic syndrome iron chelation therapy hepcidin Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	iron overload myelodysplastic syndrome iron chelation therapy hepcidin Diseases of the blood and blood-forming organs RC633-647.5 Parisi S Finelli C Prognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients
description	Sarah Parisi,1 Carlo Finelli2 1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy; 2IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, ItalyCorrespondence: Sarah Parisi Email sarah.parisi2@unibo.itAbstract: Iron chelation therapy (ICT) is an important tool in the treatment of transfusion-dependent lower-risk myelodysplastic syndrome (MDS) patients. ICT is effective in decreasing iron overload and consequently in limiting its detrimental effects on several organs, such as the heart, liver, and endocrine glands. Besides this effect, ICT also proved to be effective in improving peripheral cytopenia in a significant number of MDS patients, thus further increasing the clinical interest of this therapeutic tool. In the first part of the review, we will analyze the toxic effect of iron overload and its mechanism. Subsequently, we will revise the clinical role of ICT in various subsets of MDS patients (low, intermediate, and high risk MDS, patients who are candidates for allogeneic stem cell transplantation).Keywords: iron overload, myelodysplastic syndrome, iron chelation therapy, hepcidin
format	article
author	Parisi S Finelli C
author_facet	Parisi S Finelli C
author_sort	Parisi S
title	Prognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients
title_short	Prognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients
title_full	Prognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients
title_fullStr	Prognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients
title_full_unstemmed	Prognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients
title_sort	prognostic factors and clinical considerations for iron chelation therapy in myelodysplastic syndrome patients
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/13fa4193da1b4fd292ba8f964c3b6833
work_keys_str_mv	AT parisis prognosticfactorsandclinicalconsiderationsforironchelationtherapyinmyelodysplasticsyndromepatients AT finellic prognosticfactorsandclinicalconsiderationsforironchelationtherapyinmyelodysplasticsyndromepatients
_version_	1718371104789102592

Prognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients

Ejemplares similares